Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

SPECIAL REPORT: 2008 Chartbook of International Pharmaceutical Prices

Published by: Decision Resources

Published: Jun. 26, 2008 - 66 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Overview

Overall Price Differentials Among Markets

Pricing Hierarchy in Individual Markets

Price Variations by Therapeutic Area

Cardiovascular Drugs

Metabolic Disease Therapies

Immune and Infl ammatory Disease Therapies

Infectious Disease Therapies

Neurology Drugs

Psychiatric Drugs

Antineoplastic Drugs

Treatments for the Side Effects of Chemotherapy

Gastrointestinal Drugs

Prices of Biologics

Outlook and Implications for the Pharmaceutical Industry

Tables

1. Dosing Units Used for Pricing Calculations

2. Ex-Manufacturer Prices of Select Best-Selling Prescription Drugs Expressed as a Percentage of U.S. Prices

3. U.S. Prices as a Percentage of Average Prices in the Other Six Major Pharmaceutical Markets

4. French Prices as a Percentage of U.S. Prices

5. German Prices as a Percentage of U.S. Prices

6. Italian Prices as a Percentage of U.S. Prices

7. Spanish Prices as a Percentage of U.S. Prices

8. U.K. Prices as a Percentage of U.S. Prices

9. Average European Prices as a Percentage of U.S. Prices

10. Japanese Prices as a Percentage of U.S. Prices

11. Prices of Leading Cardiovascular Drugs in the Major Markets as a Percentage of U.S. Prices

12. Prices of Leading Metabolic Disease Therapies in the Major Markets as a Percentage of U.S. Prices

13. Prices of Leading Immune and Infl ammatory Disease Therapies in the Major Markets as a Percentage of U.S. Prices

14. Prices of Leading Infectious Disease Therapies in the Major Markets as a Percentage of U.S. Prices

15. Prices of Leading Neurological Disease Therapies in the Major Markets as a Percentage of U.S. Prices

16. Prices of Leading Psychiatric Drugs in the Major Markets as a Percentage of U.S. Prices

17. Prices of Leading Antineoplastic Drugs in the Major Markets as a Percentage of U.S. Prices

18. Prices of Leading Treatments for the Side Effects of Chemotherapy in the Major Markets as a Percentage of U.S. Prices

19. Prices of Leading Gastrointestinal Drugs in the Major Markets as a Percentage of U.S. Prices

20. Prices of Leading Biologics in the Major Markets as a Percentage of U.S. Prices

Figures

1. Average Prices of Leading Cardiovascular Drugs in the Major Markets as a Percentage of U.S. Prices

2. Average Prices of Leading Metabolic Disease Therapies in the Major Markets as a Percentage of U.S. Prices

3. Average Prices of Leading Immune and Infl ammatory Disease Therapies in the Major Markets as a Percentage of U.S. Prices

4. Average Prices of Leading Infectious Disease Therapies in the Major Markets as a Percentage of U.S. Prices

5. Average Prices of Leading Neurological Disease Therapies in the Major Markets as a Percentage of U.S. Prices

6. Average Prices of Leading Psychiatric Disease Therapies in the Major Markets as a Percentage of U.S. Prices

7. Average Prices of Leading Antineoplastic Drugs in the Major Markets as a Percentage of U.S. Prices

8. Average Prices of Leading Treatments for the Side Effects of Chemotherapy in the Major Markets as a Percentage of U.S. Prices

9. Average Prices of Leading Gastrointestinal Drugs in the Major Markets as a Percentage of U.S. Prices

10. Average Prices of Leading Biologics, Small-Molecule Drugs, and Pharmaceuticals Overall in the Major Markets as a Percentage of U.S. Prices

Abstract

In an increasingly globalized pharmaceutical market, drug pricing and reimbursement policies differ markedly among countries. Payers jealously guard their authority to set prices, and both they and government authorities exert growing pressure on manufacturers to cut prices. To best determine pricing, pharmaceutical companies therefore need to be aware of international price differentials; this report provides comparisons of exmanufacturer drug prices among the countries under study and by select therapeutic area.

Get the Answers You Need to Shape Your Strategy
  • European prices for the 160 drugs covered in this report vary, with German and U.K. prices on average closer to U.S. prices; in Germany, several agents are more expensive in that country than in the United States. What market conditions in these two European countries drive the price variations compared with the United States? What therapeutic areas warrant higher or lower pricing, and why? How do prices in these two countries compare with the other European counties under study?
  • Since 2006, there has been a sharp decline in Japanese prices for biologics (relative to U.S. prices), while European prices for biologics have experienced a slight increase. Why have biologics experienced different pricing trends in these two regions? How do biologics prices in the individual European markets stack up against U.S. prices?
  • As in previous years, average wholesale prices in the United States again increased; conversely, the annual infl ation rate for drug costs was at its lowest point in 30 years, one-quarter of what it was two years ago. What changes in the U.S. market have contributed to this competing push-pull in pricing trends?
  • A new wrinkle to government-imposed Japanese price controls now cuts the prices of entire drug classes in response to increased sales of a drug in that class. What other government or market factors affect drug pricing in Japan? What is the Japanese government’s rationale for such stringent price-control policies?
Scope
  • Overall price differentials among markets: ex-manufacturer prices of 160 best-selling drugs in six major markets (France, Germany, Italy, Spain, United Kingdom, Japan) relative to U.S. prices.
  • Pricing hierarchy in individual markets: U.S. price of each of the 160 drugs under review as a percentage of average prices in the six other markets under review; pricing hierarchy in individual European markets, Japan, and the five European markets overall as a percentage of U.S. prices.
  • Price variations by therapeutic area: coverage of 160 of the world’s best-selling prescription drugs in 2007, including 20 products in each of 7 therapeutic areas (cardiovascular disease, metabolic disorders, immune/infl ammatory disorders, infectious disease, neurology, psychiatry, and oncology), 10 treatments for side effects of chemotherapy, and 10 gastrointestinal drugs.
  • Prices of biologics: prices as a percentage of U.S. prices for 21 biologics in the six other markets under study.
  • Outlook and implications: continued scrutiny and criticism of prescription drug prices by payers in the United States; ongoing strict government control of drug prices in Europe, achieved by mandatory price freezes, general price cuts, and reference pricing; continued government-imposed biennial price revisions in Japan.
  • Pharmaceutical Pricing Chartbook Series: This report is part of a series that examines pricing trends for the world’s best-selling branded drugs and for molecules that have been subject to generics competition in recent years. The reports’ wealth of data and analysis on pricing differentials in seven major markets will be invaluable to companies that need to understand detailed pricing trends in key markets.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008